News
NOTV
0.3328
-7.89%
-0.0285
Inotiv Is Maintained at Buy by Lake Street
Dow Jones · 15h ago
Inotiv Price Target Cut to $1.50/Share From $3.00 by Lake Street
Dow Jones · 15h ago
Inotiv price target lowered to $1.50 from $3 at Lake Street
TipRanks · 21h ago
Inotiv Earnings Call: DSA Momentum vs. Debt Risks
TipRanks · 1d ago
Inotiv targets DSA margin improvements and site optimization amid 12% DSA revenue growth
Seeking Alpha · 1d ago
Inotiv GAAP EPS of -$0.83 misses by $0.19, revenue of $120.88M in-line
Seeking Alpha · 1d ago
Contract research firm Inotiv's Q1 operating loss widens
Reuters · 1d ago
Inotiv reports Q1 EPS (83c) vs. ($1.02) last year
TipRanks · 1d ago
Inotiv Earnings Report: Q1 Overview
Benzinga · 1d ago
Inotiv Q1 EPS $(0.83) Misses $(0.64) Estimate, Sales $120.879M Miss $120.909M Estimate
Benzinga · 1d ago
Inotiv Inc. meldet für das erste Quartal (Q1) 2026 einen operativen Verlust von 16,3 Mio. USD mit einem Anstieg um 5,3 Prozent
Reuters · 1d ago
Inotiv Inc. Q1 operating loss rises 5.3% to USD 16.3 million
Reuters · 1d ago
*Inotiv 1Q Rev $120.9M >NOTV
Dow Jones · 1d ago
*Inotiv 1Q Loss/Shr 83c >NOTV
Dow Jones · 1d ago
BRIEF-Inotiv Q1 Revenue USD 120.9 Million
Reuters · 1d ago
INOTIV REPORTS FIRST QUARTER FINANCIAL RESULTS FOR FISCAL 2026 AND PROVIDES BUSINESS UPDATE
Reuters · 1d ago
Press Release: Inotiv Reports First Quarter Financial Results for Fiscal 2026 and Provides Business Update
Dow Jones · 1d ago
Press Release: Inotiv Reports First Quarter -4-
Dow Jones · 1d ago
Earnings Scheduled For February 9, 2026
Benzinga · 1d ago
Weekly Report: what happened at NOTV last week (0202-0206)?
Weekly Report · 2d ago
More
Webull provides a variety of real-time NOTV stock news. You can receive the latest news about Inotiv Inc through multiple platforms. This information may help you make smarter investment decisions.
About NOTV
Inotiv, Inc. is a contract research company engaged in providing nonclinical and analytical drug discovery and development services to the pharmaceutical and medical device industries and selling a range of research-quality animals and diets to the same industries, as well as academia and government clients. Its products and services focus on bringing new drugs and medical devices through the discovery and preclinical phases of development. It operates through two segments: Discovery and Safety Assessment (DSA) and Research Models and Services (RMS). Through DSA segment, it supports the discovery, nonclinical development and clinical development needs of researchers and clinicians for primarily small molecule drug candidates, as well as biotherapeutics and biomedical devices. Through RMS segment, it offers access to a range of small and large research models for basic research and drug discovery and development, as well as specialized models for specific diseases and therapeutic areas.